NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

5415.00 -18.00 (-0.33%)

98,286 NSE+BSE Volume

NSE 29 Sep, 2025 1:23 PM (IST)

64,744.4

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

17 Nov 2017

5415.00

-0.33%

Result Update:Alkem Lab

Buy: Alkem Laboratories Ltd.

Target

Axis Direct

Alkem's domestic formulations business (76% of sales) grew 15% YoY (grew 22% YoY adj for excise duty impact, realization gap under GST) led by channel restocking. Gross margin improved 118 bps YoY, while EBITDA margin improved 574 bps driven by operating leverage.

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

11 Nov 2017

5415.00

-0.33%

Alkem Labs (2QFY18): Marching on. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Considering ALKEM's business model (high % of branded revenues), growth trajectory, and regulatory track record, we upgrade our earnings multiple to 22x from 21x and maintain BUY with a revised TP of Rs 2,100 (22x Sep19E). Channel re-stocking post GST implantation was the key reason behind Alkem Labs (ALKEM) revenue uptick and strong EBITDA margin in 2QFY18. Revenue came in at Rs 18.7bn, up 14% YoY, with the domestic business growing 15% YoY. Operating leverage on channel compensation led to a sharp jump in the EBITDA margin to 24.7%, expanding ~575bps YoY. PAT came in at Rs 3.2bn, up 13% YoY.

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

11 Nov 2017

5415.00

-0.33%

Alkem Laboratories: Strong numbers; operating leverage impact visible

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

domestic business grew robustly by 15% YoY to INR14.1b, led by channel refilling post GST. The company is expanding its presence in the domestic business via new product launches and expanding into new therapies. Alkem maintained its guidance for mid-teens growth in FY18; with channel refilling post GST, it is confident to achieve this target. Inventory levels are at ~30...

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6400.0 on 19 Sep, 2025.

Alkem Laboratories Ltd.

10 Oct 2017

5415.00

-0.33%

Pharmaceuticals: 2QFY18E Results Preview

Top Picks: Alkem Laboratories Ltd.

HDFC Securities

Top picks: CDH, LPC, ALKEM, DISH and GRAN Unlike the last two quarters, the Indian pharma sector will witness some relief in 2QFY18, largely led by certain one-off factors. Channel re-stocking will help many companies in the India branded business, and a couple of significant launches in the US market will provide a further boost. For our coverage universe, we foresee a 15% sequential jump in revenues, and the EBITDA margin to move up to 22% from 18% QoQ. On a YoY basis, we expect single-digit top-line growth. 2HFY18 is again likely to be soft, with no visibility on resolution of the FDA issues of large companies like SUNP and DRRD.

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6400.0 on 19 Sep, 2025.

Alkem Laboratories Ltd.

18 Aug 2017

5415.00

-0.33%

Result Update - Alkem

Buy: Alkem Laboratories Ltd.

Target

Axis Direct

Alkems domestic formulations business (69% of sales) declined 21% YoY due to destocking on GST transition and higher YoY pricing erosion in anti-infective portfolio (~40% of domestic sales).

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Laboratories Ltd.

12 Aug 2017

5415.00

-0.33%

Alkem Labs (1QFY18): GST storm subsides. Upgrade to BUY

Buy: Alkem Laboratories Ltd.

Recommendation Target

HDFC Securities

With valuations now lending some support, we upgrade our rating to BUY with a TP of Rs 2,000 (21x Jun19E). Channel destocking prior to GST implementation led to erosion of nearly a month of sales for Alkem Labs (ALKEM) in 1QFY18. Revenue came in at Rs 13bn, down 11% YoY, with the domestic business declining 21% YoY. Operating de-leverage and additional expenses on channel compensation led to a sharp fall in the EBITDA margin to 7.3%, contracting ~1100bps YoY. PAT was Rs 716mn, down 70% YoY.

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Laboratories Ltd.

31 May 2017

5415.00

-0.33%

Result Updates

Buy: Alkem Laboratories Ltd.

Recommendation Target

Angel Broking

Alkem reported yoy revenue grew of 9% in 4QFY17. Domestic revenue grew by 7% yoy to Rs856cr while exports grew by 14.5% to Rs385cr. US revenue grew by 19.4% yoy to Rs291cr. Other exports were flat at Rs95cr. Domestic business contributed 69% of the total revenue during the quarter. Exports mix remains unchanged (vs. 3QFY17), with US contr..

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

29 May 2017, 09:37AM

5415.00

-0.33%

Alkem (4QFY17): Near-term disruption. Maintain NEUTRAL

Neutral: Alkem Laboratories Ltd.

Target

HDFC Securities

The fourth quarter is seasonally weak for ALKEM, and 4QFY17 was no different. The top-line grew by a mere 9.5% YoY, affected by channel de-stocking and seasonality. EBITDA margin at 11.9% and PAT at ~1.4bn also missed our estimates by ~370bps and 16% respectively.

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6400.0 on 19 Sep, 2025.

Is Alkem Laboratories Ltd. worth buying?

139 Votes:

Buy 79.14%

Sell 14.39%

Hold 6.47%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf